



## Clinical trial results:

### Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)

#### Summary

EudraCT number	2009-012269-71
Trial protocol	DE ES SE DK FR IE HU CZ GB IT
Global end of trial date	18 November 2013

#### Results information

Result version number	v1 (current)
This version publication date	28 October 2016
First version publication date	28 October 2016

#### Trial information

##### Trial identification

Sponsor protocol code	BC22140
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01042769
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	global.trial_information@roche.com, F. Hoffmann-La Roche AG,, +41 61 687 83333, global.trial_information@roche.com
Scientific contact	+41 61 6878333,, Roche Trial Information Hotline,, +41 61 687 83333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 December 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	18 November 2013
Global end of trial reached?	Yes
Global end of trial date	18 November 2013
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To determine whether aleglitazar reduces cardiovascular mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and T2D.

Protection of trial subjects:

All participants signed an informed consent form before enrollment into the study.

Background therapy:

Contemporary evidence-based medical care for ACS (e.g., antiplatelets, beta-blockers, ACE-inhibitors, and statins), and diabetes (e.g., diet, exercise, antihyperglycemic medications).

Evidence for comparator: -

Actual start date of recruitment	03 May 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	China: 631
Country: Number of subjects enrolled	India: 602
Country: Number of subjects enrolled	Korea, Republic of: 233
Country: Number of subjects enrolled	Thailand: 232
Country: Number of subjects enrolled	Malaysia: 120
Country: Number of subjects enrolled	Australia: 98
Country: Number of subjects enrolled	New Zealand: 61
Country: Number of subjects enrolled	Russian Federation: 42
Country: Number of subjects enrolled	Poland: 638
Country: Number of subjects enrolled	Spain: 448
Country: Number of subjects enrolled	Germany: 279
Country: Number of subjects enrolled	Hungary: 251
Country: Number of subjects enrolled	Italy: 157
Country: Number of subjects enrolled	United Kingdom: 134
Country: Number of subjects enrolled	Sweden: 132
Country: Number of subjects enrolled	Czech Republic: 124
Country: Number of subjects enrolled	Netherlands: 94
Country: Number of subjects enrolled	France: 92
Country: Number of subjects enrolled	Romania: 90
Country: Number of subjects enrolled	Ireland: 43

Country: Number of subjects enrolled	Denmark: 28
Country: Number of subjects enrolled	United States: 1094
Country: Number of subjects enrolled	Canada: 545
Country: Number of subjects enrolled	Mexico: 369
Country: Number of subjects enrolled	Brazil: 533
Country: Number of subjects enrolled	Argentina: 156
Worldwide total number of subjects	7226
EEA total number of subjects	2510

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4836
From 65 to 84 years	2354
85 years and over	36

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

An Eligibility Screening Form [ESF] documenting the investigator's assessment of each screened patient with regard to the protocol's inclusion and exclusion criteria was completed by the investigator.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Aleglitazar

Arm description:

Aleglitazar 150 µg tablet

Arm type	Experimental
Investigational medicinal product name	Aleglitazar
Investigational medicinal product code	Ro 72-8804/F23
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Once daily

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Placebo

Arm type	Placebo
Investigational medicinal product name	Matching placebo tablet
Investigational medicinal product code	(Ro 72-8804/F20)
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Once daily

Number of subjects in period 1	Aleglitazar	Placebo
Started	3616	3610
Completed	3244	3243
Not completed	372	367
Adverse event, serious fatal	147	139

Consent withdrawn by subject	120	108
Missing information	-	1
Lost to follow-up	105	119

## Baseline characteristics

### Reporting groups

Reporting group title	Aleglitazar
-----------------------	-------------

Reporting group description:

Aleglitazar 150 µg tablet

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo

Reporting group values	Aleglitazar	Placebo	Total
Number of subjects	3616	3610	7226
Age categorical			
Units: Subjects			
Adults (18-64 years)	2374	2462	4836
From 65-84 years	1220	1134	2354
85 years and over	21	14	35
Not recorded	1	0	1
Gender categorical			
Units: Subjects			
Female	974	991	1965
Male	2641	2619	5260
Not recorded	1	0	1

## End points

### End points reporting groups

Reporting group title	Aleglitazar
Reporting group description:	
Aleglitazar 150 µg tablet	
Reporting group title	Placebo
Reporting group description:	
Placebo	

### Primary: Number of patients with first occurrence of any component of a composite of cardiovascular death, nonfatal myocardial infarction and non-fatal stroke as adjudicated by the Clinical Events Committee (CEC)

End point title	Number of patients with first occurrence of any component of a composite of cardiovascular death, nonfatal myocardial infarction and non-fatal stroke as adjudicated by the Clinical Events Committee (CEC)
End point description:	
End point type	Primary
End point timeframe:	
3 years	

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3616	3610		
Units: Patients	344	362		

### Statistical analyses

Statistical analysis title	Primary outcome measure
Comparison groups	Placebo v Aleglitazar
Number of subjects included in analysis	7226
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.566
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.11

---

**Secondary: Number of patients with other cardiovascular outcomes**

---

End point title	Number of patients with other cardiovascular outcomes
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

3 years

---

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3616	3610		
Units: Patients				
Any cardiovascular death	112	98		
Any non-fatal myocardial infarction	212	239		
Any non-fatal stroke	49	52		
All-cause mortality	148	139		
Hosp. for unstable angina	118	156		
Hosp. for heart failure	122	100		

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Mean absolute change from baseline to end of treatment in glycated hemoglobin (HbA1c)**

---

End point title	Mean absolute change from baseline to end of treatment in glycated hemoglobin (HbA1c)
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

3 years

---

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3362	3371		
Units: Value				
arithmetic mean (standard deviation)	-0.7 (± 1.5)	-0.1 (± 1.5)		



## Statistical analyses

No statistical analyses for this end point

### Secondary: Mean percentage change from baseline to end of treatment in low-density lipoprotein cholesterol (LDL-C)

End point title	Mean percentage change from baseline to end of treatment in low-density lipoprotein cholesterol (LDL-C)
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

3 years

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3243	3212		
Units: Value				
arithmetic mean (standard deviation)	23.1 (± 50.8)	16.6 (± 49)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Mean percentage change from baseline to end of treatment in high-density lipoprotein cholesterol (HDL-C)

End point title	Mean percentage change from baseline to end of treatment in high-density lipoprotein cholesterol (HDL-C)
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

3 years

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3301	3289		
Units: Value				
arithmetic mean (standard deviation)	24.8 (± 27.4)	10.3 (± 23.1)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean percentage change from baseline to end of treatment in triglycerides (TG)

End point title	Mean percentage change from baseline to end of treatment in triglycerides (TG)
End point description:	
End point type	Secondary
End point timeframe:	
3 years	

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3302	3290		
Units: Value				
arithmetic mean (standard deviation)	-13.1 (± 46.5)	22 (± 67.8)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean percentage change from baseline to end of treatment in apolipoprotein A-I (ApoA1)

End point title	Mean percentage change from baseline to end of treatment in apolipoprotein A-I (ApoA1)
End point description:	
End point type	Secondary
End point timeframe:	
3 years	

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3296	3279		
Units: Value				
arithmetic mean (standard deviation)	10.3 ( $\pm$ 20.3)	7.9 ( $\pm$ 18.3)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean percentage change from baseline to end of treatment in apolipoprotein B (ApoB)

End point title	Mean percentage change from baseline to end of treatment in apolipoprotein B (ApoB)
End point description:	
End point type	Secondary
End point timeframe:	
3 years	

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3296	3279		
Units: Value				
arithmetic mean (standard deviation)	4.8 ( $\pm$ 33.2)	10.2 ( $\pm$ 32.8)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean absolute change from baseline to end of treatment in fibrinogen-C

End point title	Mean absolute change from baseline to end of treatment in fibrinogen-C
End point description:	
End point type	Secondary
End point timeframe:	
3 years	

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3151	3145		
Units: Value				
arithmetic mean (standard deviation)	-110.1 ( $\pm$ 139.5)	-68.2 ( $\pm$ 145.2)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Median percent change from baseline to end of treatment (Q1 – Q3) in high-sensitivity C-reactive protein (hs-CRP-C)

End point title	Median percent change from baseline to end of treatment (Q1 – Q3) in high-sensitivity C-reactive protein (hs-CRP-C)
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:  
3 years

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3287	3291		
Units: Value				
median (inter-quartile range (Q1-Q3))	-31.5 (-70.7 to 35)	-23 (-64.9 to 43.7)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean percentage change from baseline to end of treatment in adiponectin

End point title	Mean percentage change from baseline to end of treatment in adiponectin
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:  
3 years

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3259	3235		
Units: Value				
arithmetic mean (standard deviation)	212 ( $\pm$ 214.2)	16.2 ( $\pm$ 57.4)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of patients with at least one adverse event

End point title	Number of patients with at least one adverse event
End point description:	
End point type	Secondary
End point timeframe:	
3 years	

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3587	3587		
Units: Patients	2719	2515		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Total number of adverse events

End point title	Total number of adverse events
End point description:	
End point type	Secondary
End point timeframe:	
3 years	

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3587	3587		
Units: AEs	11853	10252		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Deaths

End point title	Deaths
End point description:	
End point type	Secondary
End point timeframe:	
3 years	

End point values	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3587	3587		
Units: Deaths	148	139		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Patients with at least one serious adverse event

End point title	Patients with at least one serious adverse event
End point description:	
End point type	Secondary
End point timeframe:	
3 years	

<b>End point values</b>	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3587	3587		
Units: Patients	901	833		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Patients with adverse events leading to withdrawal from treatment

End point title	Patients with adverse events leading to withdrawal from treatment
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

3 years

<b>End point values</b>	Aleglitazar	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3587	3587		
Units: Patients	286	165		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 89 weeks.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	Aleglitazar
-----------------------	-------------

Reporting group description:

Aleglitazar 150 µg tablet

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo

Serious adverse events	Aleglitazar	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	1015 / 3587 (28.30%)	947 / 3587 (26.40%)	
number of deaths (all causes)	2	2	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
PROSTATE CANCER			
subjects affected / exposed	11 / 3587 (0.31%)	13 / 3587 (0.36%)	
occurrences causally related to treatment / all	1 / 11	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLON CANCER			
subjects affected / exposed	5 / 3587 (0.14%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	1 / 5	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
ADENOCARCINOMA OF COLON			
subjects affected / exposed	4 / 3587 (0.11%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 4	2 / 3	
deaths causally related to treatment / all	0 / 2	0 / 0	
BLADDER CANCER			



subjects affected / exposed	4 / 3587 (0.11%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	2 / 4	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BREAST CANCER</b>			
subjects affected / exposed	2 / 3587 (0.06%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LUNG ADENOCARCINOMA</b>			
subjects affected / exposed	3 / 3587 (0.08%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	1 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LUNG NEOPLASM MALIGNANT</b>			
subjects affected / exposed	3 / 3587 (0.08%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>BASAL CELL CARCINOMA</b>			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BLADDER TRANSITIONAL CELL CARCINOMA</b>			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PANCREATIC CARCINOMA METASTATIC</b>			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
<b>ADENOCARCINOMA GASTRIC</b>			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTRIC CANCER</b>			

subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
METASTASES TO LIVER			
subjects affected / exposed	3 / 3587 (0.08%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RECTAL CANCER			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL CANCER			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL CELL CARCINOMA			
subjects affected / exposed	3 / 3587 (0.08%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SQUAMOUS CELL CARCINOMA OF LUNG			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
B-CELL LYMPHOMA			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BILIARY CANCER METASTATIC			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
BREAST CANCER METASTATIC			

subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NON-SMALL CELL LUNG CANCER			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
PANCREATIC CARCINOMA			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
UTERINE LEIOMYOMA			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE LEUKAEMIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE MYELOID LEUKAEMIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ADENOCARCINOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ADENOCARCINOMA PANCREAS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ADENOID CYSTIC CARCINOMA			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BENIGN NEOPLASM OF EPIDIDYMIS</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BENIGN RENAL NEOPLASM</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BLADDER CANCER RECURRENT</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BLADDER NEOPLASM</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BOWEN'S DISEASE</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BREAST NEOPLASM</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>BRONCHIAL CARCINOMA</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>CARCINOID TUMOUR OF THE DUODENUM</b>			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CERVIX CARCINOMA STAGE II			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHRONIC LYMPHOCYTIC LEUKAEMIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CLEAR CELL RENAL CELL CARCINOMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHRONIC MYELOMONOCYTIC LEUKAEMIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLON CANCER METASTATIC			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
EAR NEOPLASM MALIGNANT			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENDOMETRIAL CANCER STAGE II			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
GASTROINTESTINAL CARCINOMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
GASTROINTESTINAL NEOPLASM			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
HEPATIC CANCER METASTATIC			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL TRACT ADENOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HUERTHLE CELL CARCINOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTESTINAL ADENOCARCINOMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LARYNGEAL SQUAMOUS CELL CARCINOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INVASIVE LOBULAR BREAST CARCINOMA			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LENTIGO MALIGNA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LIPOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG ADENOCARCINOMA METASTATIC			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG CANCER METASTATIC			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MALIGNANT ASCITES			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MALIGNANT MELANOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MALIGNANT PLEURAL EFFUSION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MALIGNANT NEOPLASM OF CONJUNCTIVA			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MANTLE CELL LYMPHOMA STAGE IV			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MEDIASTINUM NEOPLASM			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
MENINGIOMA BENIGN			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTASES TO ADRENALS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTASES TO BONE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTASES TO LYMPH NODES			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
METASTASES TO RETROPERITONEUM			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
METASTATIC BRONCHIAL CARCINOMA			



subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>METASTATIC MALIGNANT MELANOMA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>MYELODYSPLASTIC SYNDROME</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>METASTATIC RENAL CELL CARCINOMA</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>NON-HODGKIN'S LYMPHOMA</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>NEUROMA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>NON-SMALL CELL LUNG CANCER STAGE I</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>NON-SMALL CELL LUNG CANCER STAGE IIIA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

OESOPHAGEAL ADENOCARCINOMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
OESOPHAGEAL CARCINOMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PROSTATE CANCER METASTATIC			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RECTAL ADENOCARCINOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RECTOSIGMOID CANCER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL NEOPLASM			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SALIVARY GLAND CANCER			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SMALL CELL LUNG CANCER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SQUAMOUS CELL CARCINOMA OF THE TONGUE			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>T-CELL LYMPHOMA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>THYROID ADENOMA</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>URETHRAL CANCER</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>UTERINE CANCER</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Vascular disorders</b>			
<b>HYPERTENSION</b>			
subjects affected / exposed	10 / 3587 (0.28%)	12 / 3587 (0.33%)	
occurrences causally related to treatment / all	1 / 10	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPERTENSIVE CRISIS</b>			
subjects affected / exposed	8 / 3587 (0.22%)	10 / 3587 (0.28%)	
occurrences causally related to treatment / all	0 / 8	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOTENSION</b>			
subjects affected / exposed	9 / 3587 (0.25%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PERIPHERAL ISCHAEMIA</b>			

subjects affected / exposed	4 / 3587 (0.11%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
INTERMITTENT CLAUDICATION			
subjects affected / exposed	3 / 3587 (0.08%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE			
subjects affected / exposed	5 / 3587 (0.14%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
AORTIC ANEURYSM			
subjects affected / exposed	5 / 3587 (0.14%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACCELERATED HYPERTENSION			
subjects affected / exposed	2 / 3587 (0.06%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEEP VEIN THROMBOSIS			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
EXTREMITY NECROSIS			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTERIOSCLEROSIS			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
DIABETIC VASCULAR DISORDER			

subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATOMA			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOVOLAEMIC SHOCK			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
PERIPHERAL VASCULAR DISORDER			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSIVE EMERGENCY			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ILIAC ARTERY OCCLUSION			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
MALIGNANT HYPERTENSION			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
THROMBOPHLEBITIS			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTERIAL INSUFFICIENCY			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTERIAL SPASM			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CIRCULATORY COLLAPSE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
DIABETIC MICROANGIOPATHY			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMORAL ARTERY ANEURYSM			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMORAL ARTERY EMBOLISM			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FLUSHING			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ISCHAEMIC LIMB PAIN			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
JUGULAR VEIN THROMBOSIS			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LERICHE SYNDROME			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LYMPHOEDEMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NECROSIS ISCHAEMIC			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL ARTERY ANEURYSM			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL ARTERY THROMBOSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SHOCK HAEMORRHAGIC			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VARICOSE VEIN			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULAR OCCLUSION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
KNEE ARTHROPLASTY			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
AORTIC VALVE REPLACEMENT			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CATARACT OPERATION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC PACEMAKER REPLACEMENT			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FOOT AMPUTATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ILEOSTOMY			



subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
IMPLANTABLE DEFIBRILLATOR INSERTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
IMPLANTABLE DEFIBRILLATOR REMOVAL			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LEG AMPUTATION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PROSTATECTOMY			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SCAR EXCISION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
THERAPY CHANGE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TOE AMPUTATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRANSURETHRAL PROSTATECTOMY			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	93 / 3587 (2.59%)	73 / 3587 (2.04%)	
occurrences causally related to treatment / all	2 / 118	4 / 81	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEATH			
subjects affected / exposed	9 / 3587 (0.25%)	14 / 3587 (0.39%)	
occurrences causally related to treatment / all	0 / 9	1 / 14	
deaths causally related to treatment / all	0 / 9	1 / 14	
SUDDEN DEATH			
subjects affected / exposed	6 / 3587 (0.17%)	10 / 3587 (0.28%)	
occurrences causally related to treatment / all	1 / 6	0 / 10	
deaths causally related to treatment / all	1 / 6	0 / 10	
SUDDEN CARDIAC DEATH			
subjects affected / exposed	9 / 3587 (0.25%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 9	0 / 3	
deaths causally related to treatment / all	0 / 9	0 / 3	
OEDEMA PERIPHERAL			
subjects affected / exposed	6 / 3587 (0.17%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	2 / 6	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHEST DISCOMFORT			
subjects affected / exposed	5 / 3587 (0.14%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	1 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYREXIA			
subjects affected / exposed	2 / 3587 (0.06%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHEST PAIN			

subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
FATIGUE			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
IMPAIRED HEALING			
subjects affected / exposed	4 / 3587 (0.11%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASTHENIA			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC DEATH			
subjects affected / exposed	3 / 3587 (0.08%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 3	0 / 0	
LOCAL SWELLING			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MALAISE			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHILLS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CYST			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE BREAKAGE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE DISLOCATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
DRUG INTOLERANCE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ELECTROCUTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
GAIT DISTURBANCE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GENERALISED OEDEMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HERNIA OBSTRUCTIVE			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
IMPLANT SITE HAEMORRHAGE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFLAMMATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MEDICAL DEVICE COMPLICATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MEDICAL DEVICE PAIN			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MULTI-ORGAN FAILURE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NECROBIOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SURGICAL FAILURE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
ALLERGY TO ARTHROPOD STING			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONTRAST MEDIA ALLERGY			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DRUG HYPERSENSITIVITY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FOOD ALLERGY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERSENSITIVITY			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRANSPLANT REJECTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
PHYSICAL ASSAULT			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
BENIGN PROSTATIC HYPERPLASIA			
subjects affected / exposed	2 / 3587 (0.06%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	

PROSTATITIS			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ERECTILE DYSFUNCTION			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
OVARIAN CYST			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACQUIRED HYDROCELE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BREAST DYSPLASIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BREAST HAEMATOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENDOMETRIAL HYPERPLASIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
EPIDIDYMITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GENITAL TRACT INFLAMMATION			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GYNAECOMASTIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MENORRHAGIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PROSTATIC OBSTRUCTION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VAGINAL HAEMORRHAGE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VULVAL ULCERATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
subjects affected / exposed	22 / 3587 (0.61%)	14 / 3587 (0.39%)	
occurrences causally related to treatment / all	2 / 22	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			
subjects affected / exposed	17 / 3587 (0.47%)	15 / 3587 (0.42%)	
occurrences causally related to treatment / all	0 / 25	0 / 17	
deaths causally related to treatment / all	0 / 1	0 / 0	
PULMONARY OEDEMA			



subjects affected / exposed	9 / 3587 (0.25%)	12 / 3587 (0.33%)	
occurrences causally related to treatment / all	1 / 9	2 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLEURAL EFFUSION			
subjects affected / exposed	8 / 3587 (0.22%)	9 / 3587 (0.25%)	
occurrences causally related to treatment / all	0 / 9	1 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY EMBOLISM			
subjects affected / exposed	10 / 3587 (0.28%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 11	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 0	
RESPIRATORY FAILURE			
subjects affected / exposed	7 / 3587 (0.20%)	7 / 3587 (0.20%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 3	0 / 3	
ACUTE PULMONARY OEDEMA			
subjects affected / exposed	5 / 3587 (0.14%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 7	2 / 8	
deaths causally related to treatment / all	0 / 2	0 / 1	
PNEUMOTHORAX			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSPNOEA EXERTIONAL			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	1 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE RESPIRATORY FAILURE			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASTHMA			

subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
COUGH			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLEURISY			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONIA ASPIRATION			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
PNEUMONITIS			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY HYPERTENSION			
subjects affected / exposed	3 / 3587 (0.08%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
SLEEP APNOEA SYNDROME			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHITIS CHRONIC			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
EPISTAXIS			

subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOXIA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PLEURITIC PAIN</b>			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PULMONARY FIBROSIS</b>			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>RESPIRATORY DISTRESS</b>			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>ALLERGIC BRONCHITIS</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CHRONIC RESPIRATORY FAILURE</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DYSPHONIA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HAEMOPTYSIS</b>			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMOTHORAX			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HICCUPS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYDROPNEUMOTHORAX			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTERSTITIAL LUNG DISEASE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NASAL POLYPS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ORTHOPNOEA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMOMEDIASTINUM			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY THROMBOSIS			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RESPIRATORY ARREST			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Psychiatric disorders			
DEPRESSION			
subjects affected / exposed	4 / 3587 (0.11%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ALCOHOL WITHDRAWAL SYNDROME			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DELIRIUM			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUICIDE ATTEMPT			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ALCOHOL ABUSE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANXIETY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BREATHING-RELATED SLEEP DISORDER			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COMPLETED SUICIDE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
DELIRIUM TREMENS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DRUG DEPENDENCE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HOMICIDAL IDEATION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MENTAL STATUS CHANGES			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANIC ATTACK			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PSYCHOTIC DISORDER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SOMATISATION DISORDER			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STRESS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUICIDAL IDEATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
CHOLECYSTITIS ACUTE			
subjects affected / exposed	9 / 3587 (0.25%)	6 / 3587 (0.17%)	
occurrences causally related to treatment / all	1 / 9	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLECYSTITIS			
subjects affected / exposed	6 / 3587 (0.17%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLELITHIASIS			
subjects affected / exposed	6 / 3587 (0.17%)	7 / 3587 (0.20%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
BILE DUCT STONE			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLANGITIS			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
BILIARY COLIC			

subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BILE DUCT OBSTRUCTION</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CHOLANGITIS ACUTE</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CHOLECYSTITIS CHRONIC</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CIRRHOSIS ALCOHOLIC</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HAEMOBILIA</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HEPATIC CIRRHOSIS</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HEPATIC FAILURE</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HEPATITIS</b>			



subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATITIS ACUTE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYDROCHOLECYSTIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
JAUNDICE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LIVER DISORDER			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
BLOOD CREATININE INCREASED			
subjects affected / exposed	10 / 3587 (0.28%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	7 / 10	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTERNATIONAL NORMALISED RATIO INCREASED			
subjects affected / exposed	4 / 3587 (0.11%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BLOOD CREATINE PHOSPHOKINASE INCREASED			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	2 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
BLOOD PRESSURE INCREASED			

subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
EJECTION FRACTION DECREASED			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
TROPONIN INCREASED			
subjects affected / exposed	3 / 3587 (0.08%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BLOOD GLUCOSE INCREASED			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
WEIGHT DECREASED			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRANSAMINASES INCREASED			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
WEIGHT INCREASED			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TROPONIN I INCREASED			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ALANINE AMINOTRANSFERASE INCREASED			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BLOOD BILIRUBIN INCREASED</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BLOOD POTASSIUM DECREASED</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BLOOD PRESSURE DECREASED</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BODY TEMPERATURE INCREASED</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BLOOD URINE PRESENT</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CARDIAC ENZYMES INCREASED</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ELECTROCARDIOGRAM T WAVE INVERSION</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>EXERCISE TEST ABNORMAL</b>			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GAMMA-GLUTAMYLTRANSFERASE INCREASED</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GENERAL PHYSICAL CONDITION ABNORMAL</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GLOMERULAR FILTRATION RATE DECREASED</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HAEMATOCRIT DECREASED</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HAEMOGLOBIN DECREASED</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HEPATIC ENZYME INCREASED</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE INCREASED</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Injury, poisoning and procedural complications			
FEMUR FRACTURE			
subjects affected / exposed	7 / 3587 (0.20%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	1 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
FALL			
subjects affected / exposed	7 / 3587 (0.20%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
HIP FRACTURE			
subjects affected / exposed	3 / 3587 (0.08%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANKLE FRACTURE			
subjects affected / exposed	4 / 3587 (0.11%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HUMERUS FRACTURE			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBDURAL HAEMATOMA			
subjects affected / exposed	5 / 3587 (0.14%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FOOT FRACTURE			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 3587 (0.00%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	

LACERATION			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULAR PSEUDOANEURYSM			
subjects affected / exposed	0 / 3587 (0.00%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONCUSSION			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
CORONARY ARTERY RESTENOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
INCISIONAL HERNIA			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
MENISCUS INJURY			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL HAEMATOMA			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL COMPRESSION FRACTURE			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
THORACIC VERTEBRAL FRACTURE			

subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TOXICITY TO VARIOUS AGENTS			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHEST INJURY			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CRANIOCEREBRAL INJURY			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
COMMINUTED FRACTURE			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
FACIAL BONES FRACTURE			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMORAL NECK FRACTURE			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
JOINT INJURY			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
LIMB INJURY			

subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOWER LIMB FRACTURE			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PATELLA FRACTURE			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PUBIS FRACTURE			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ROAD TRAFFIC ACCIDENT			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
RADIUS FRACTURE			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBDURAL HAEMORRHAGE			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
TENDON RUPTURE			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
THERMAL BURN			



subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>TIBIA FRACTURE</b>			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ACCIDENT</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ACCIDENTAL OVERDOSE</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ACETABULUM FRACTURE</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ALCOHOL POISONING</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>AVULSION FRACTURE</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BONE FISSURE</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>FIBULA FRACTURE</b>			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTROINTESTINAL INJURY</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HAND FRACTURE</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>IMPACTED FRACTURE</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HEAD INJURY</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>JOINT DISLOCATION</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LIGAMENT SPRAIN</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LIMB TRAUMATIC AMPUTATION</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LUMBAR VERTEBRAL FRACTURE</b>			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MECHANICAL VENTILATION COMPLICATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MULTIPLE INJURIES			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OVERDOSE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PELVIC FRACTURE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPROSTHETIC FRACTURE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL SWELLING			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
POSTOPERATIVE RESPIRATORY FAILURE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
POSTPERICARDIOTOMY SYNDROME			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY CONTUSION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RESPIRATORY FUME INHALATION DISORDER			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RIB FRACTURE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL FRACTURE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STERNAL FRACTURE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
UPPER LIMB FRACTURE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VACCINATION COMPLICATION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULAR GRAFT OCCLUSION			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VASCULAR GRAFT THROMBOSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VITH NERVE INJURY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
WOUND DEHISCENCE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
WOUND SECRETION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
WRIST FRACTURE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
ATRIAL SEPTAL DEFECT			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYDROCELE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTROPHIC CARDIOMYOPATHY			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PHIMOSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYLORIC STENOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SYRINGOMYELIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
ANGINA PECTORIS			
subjects affected / exposed	86 / 3587 (2.40%)	87 / 3587 (2.43%)	
occurrences causally related to treatment / all	5 / 96	1 / 100	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC FAILURE			
subjects affected / exposed	109 / 3587 (3.04%)	62 / 3587 (1.73%)	
occurrences causally related to treatment / all	21 / 147	12 / 93	
deaths causally related to treatment / all	1 / 11	0 / 8	
CARDIAC FAILURE CONGESTIVE			
subjects affected / exposed	63 / 3587 (1.76%)	64 / 3587 (1.78%)	
occurrences causally related to treatment / all	14 / 82	12 / 88	
deaths causally related to treatment / all	0 / 0	0 / 2	
ATRIAL FIBRILLATION			
subjects affected / exposed	29 / 3587 (0.81%)	20 / 3587 (0.56%)	
occurrences causally related to treatment / all	1 / 40	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC ARREST			

subjects affected / exposed	13 / 3587 (0.36%)	13 / 3587 (0.36%)	
occurrences causally related to treatment / all	0 / 13	1 / 13	
deaths causally related to treatment / all	0 / 11	1 / 10	
CORONARY ARTERY DISEASE			
subjects affected / exposed	11 / 3587 (0.31%)	12 / 3587 (0.33%)	
occurrences causally related to treatment / all	0 / 13	0 / 13	
deaths causally related to treatment / all	0 / 2	0 / 3	
CARDIAC FAILURE ACUTE			
subjects affected / exposed	11 / 3587 (0.31%)	11 / 3587 (0.31%)	
occurrences causally related to treatment / all	0 / 14	1 / 12	
deaths causally related to treatment / all	0 / 1	0 / 0	
ARRHYTHMIA			
subjects affected / exposed	8 / 3587 (0.22%)	9 / 3587 (0.25%)	
occurrences causally related to treatment / all	1 / 8	1 / 9	
deaths causally related to treatment / all	0 / 1	0 / 2	
VENTRICULAR TACHYCARDIA			
subjects affected / exposed	6 / 3587 (0.17%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 6	2 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
MYOCARDIAL ISCHAEMIA			
subjects affected / exposed	7 / 3587 (0.20%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
ACUTE LEFT VENTRICULAR FAILURE			
subjects affected / exposed	5 / 3587 (0.14%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	5 / 5	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIOGENIC SHOCK			
subjects affected / exposed	7 / 3587 (0.20%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 7	1 / 2	
deaths causally related to treatment / all	5 / 5	1 / 1	
LEFT VENTRICULAR FAILURE			

subjects affected / exposed	2 / 3587 (0.06%)	7 / 3587 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 3	
<b>AORTIC VALVE STENOSIS</b>			
subjects affected / exposed	5 / 3587 (0.14%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	1 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ATRIAL FLUTTER</b>			
subjects affected / exposed	3 / 3587 (0.08%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	1 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LEFT VENTRICULAR DYSFUNCTION</b>			
subjects affected / exposed	2 / 3587 (0.06%)	6 / 3587 (0.17%)	
occurrences causally related to treatment / all	0 / 2	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>VENTRICULAR FIBRILLATION</b>			
subjects affected / exposed	3 / 3587 (0.08%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>BRADYCARDIA</b>			
subjects affected / exposed	2 / 3587 (0.06%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CARDIO-RESPIRATORY ARREST</b>			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
<b>ISCHAEMIC CARDIOMYOPATHY</b>			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>SICK SINUS SYNDROME</b>			



subjects affected / exposed	1 / 3587 (0.03%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIOVENTRICULAR BLOCK COMPLETE			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
CARDIAC DISCOMFORT			
subjects affected / exposed	1 / 3587 (0.03%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC FAILURE CHRONIC			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PALPITATIONS			
subjects affected / exposed	1 / 3587 (0.03%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
CORONARY ARTERY STENOSIS			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERICARDITIS			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIOVENTRICULAR BLOCK			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERICARDIAL EFFUSION			

subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUPRAVENTRICULAR TACHYCARDIA			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
TACHYCARDIA			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
VENTRICULAR EXTRASYSTOLES			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIAL TACHYCARDIA			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIOVENTRICULAR BLOCK SECOND DEGREE			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC ASTHMA			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
EXTRASYSTOLES			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MITRAL VALVE INCOMPETENCE			

subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RIGHT VENTRICULAR FAILURE			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTERIOSPASM CORONARY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC AMYLOIDOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
CARDIAC TAMPONADE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIOMYOPATHY ACUTE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIOPULMONARY FAILURE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
CARDIOVASCULAR DISORDER			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
CARDIOVASCULAR INSUFFICIENCY			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHRONIC LEFT VENTRICULAR FAILURE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHRONOTROPIC INCOMPETENCE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CORONARY ARTERY THROMBOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DRESSLER'S SYNDROME			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTRACARDIAC THROMBUS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOW CARDIAC OUTPUT SYNDROME			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
PRINZMETAL ANGINA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RESTRICTIVE CARDIOMYOPATHY			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>SINUS ARRHYTHMIA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>SINUS TACHYCARDIA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>STRESS CARDIOMYOPATHY</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>VENTRICULAR ARRHYTHMIA</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>VENTRICULAR FAILURE</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
<b>SYNCOPE</b>			
subjects affected / exposed	22 / 3587 (0.61%)	23 / 3587 (0.64%)	
occurrences causally related to treatment / all	0 / 23	1 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>TRANSIENT ISCHAEMIC ATTACK</b>			
subjects affected / exposed	10 / 3587 (0.28%)	9 / 3587 (0.25%)	
occurrences causally related to treatment / all	2 / 10	2 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CAROTID ARTERY STENOSIS</b>			

subjects affected / exposed	4 / 3587 (0.11%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DIZZINESS</b>			
subjects affected / exposed	2 / 3587 (0.06%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	0 / 2	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HEADACHE</b>			
subjects affected / exposed	2 / 3587 (0.06%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DIABETIC NEUROPATHY</b>			
subjects affected / exposed	4 / 3587 (0.11%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PRESYNCOPE</b>			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>VERTEBROBASILAR INSUFFICIENCY</b>			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CARPAL TUNNEL SYNDROME</b>			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CONVULSION</b>			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>EPILEPSY</b>			

subjects affected / exposed	3 / 3587 (0.08%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSIVE ENCEPHALOPATHY			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PARAESTHESIA			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIITH NERVE PARALYSIS			
subjects affected / exposed	3 / 3587 (0.08%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CAROTID ARTERIOSCLEROSIS			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COMA			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEMENTIA			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEMIPARESIS			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
MIGRAINE			

subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
SCIATICA		
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
SUBARACHNOID HAEMORRHAGE		
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1
ALCOHOLIC SEIZURE		
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
ATAXIA		
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CAROTID ARTERY ANEURYSM		
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CAROTID ARTERY DISEASE		
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CEREBRAL HAEMORRHAGE		
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
CEREBRAL ISCHAEMIA		



subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CEREBROVASCULAR INSUFFICIENCY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CERVICAL RADICULOPATHY			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CERVICOBACHIAL SYNDROME			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COGNITIVE DISORDER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENCEPHALITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENCEPHALOPATHY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEMIPLEGIC MIGRAINE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GRAND MAL CONVULSION			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOGLYCAEMIC COMA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOGLYCAEMIC SEIZURE</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOGLYCAEMIC UNCONSCIOUSNESS</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPONATRAEMIC ENCEPHALOPATHY</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LOSS OF CONSCIOUSNESS</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LUMBAR RADICULOPATHY</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>MEMORY IMPAIRMENT</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>MENINGITIS NONINFECTIVE</b>			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
METABOLIC ENCEPHALOPATHY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MONOPARESIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NERVE COMPRESSION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEURALGIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NORMAL PRESSURE HYDROCEPHALUS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POLYNEUROPATHY			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPEECH DISORDER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STATUS EPILEPTICUS			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VITH NERVE PARALYSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VOCAL CORD PARALYSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	21 / 3587 (0.59%)	18 / 3587 (0.50%)	
occurrences causally related to treatment / all	0 / 27	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
IRON DEFICIENCY ANAEMIA			
subjects affected / exposed	5 / 3587 (0.14%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
MICROCYTIC ANAEMIA			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
COAGULOPATHY			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEBRILE NEUTROPENIA			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERNICIOUS ANAEMIA			

subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMORRHAGIC ANAEMIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NORMOCHROMIC NORMOCYTIC ANAEMIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCYTOPENIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPLENIC INFARCTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
VERTIGO			
subjects affected / exposed	5 / 3587 (0.14%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
VERTIGO POSITIONAL			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MIXED DEAFNESS			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VESTIBULAR DISORDER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
CATARACT			
subjects affected / exposed	9 / 3587 (0.25%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 9	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RETINAL ARTERY OCCLUSION			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VITREOUS HAEMORRHAGE			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
AMAUROSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONJUNCTIVAL HAEMORRHAGE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETIC RETINOPATHY			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GLAUCOMA			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LENTICULAR OPACITIES			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VISUAL ACUITY REDUCED			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VISUAL IMPAIRMENT			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
UPPER GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	22 / 3587 (0.61%)	13 / 3587 (0.36%)	
occurrences causally related to treatment / all	3 / 23	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRIC ULCER HAEMORRHAGE			
subjects affected / exposed	7 / 3587 (0.20%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 7	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOWER GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	10 / 3587 (0.28%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 10	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL PAIN			
subjects affected / exposed	6 / 3587 (0.17%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
DUODENAL ULCER HAEMORRHAGE			

subjects affected / exposed	6 / 3587 (0.17%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL PAIN UPPER			
subjects affected / exposed	4 / 3587 (0.11%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	1 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCREATITIS ACUTE			
subjects affected / exposed	3 / 3587 (0.08%)	6 / 3587 (0.17%)	
occurrences causally related to treatment / all	1 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	5 / 3587 (0.14%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
INGUINAL HERNIA			
subjects affected / exposed	2 / 3587 (0.06%)	6 / 3587 (0.17%)	
occurrences causally related to treatment / all	1 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRITIS			
subjects affected / exposed	3 / 3587 (0.08%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSPEPSIA			
subjects affected / exposed	4 / 3587 (0.11%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	2 / 3587 (0.06%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 2	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
LARGE INTESTINE POLYP			



subjects affected / exposed	5 / 3587 (0.14%)	1 / 3587 (0.03%)
occurrences causally related to treatment / all	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
PANCREATITIS		
subjects affected / exposed	2 / 3587 (0.06%)	4 / 3587 (0.11%)
occurrences causally related to treatment / all	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
GASTRIC ULCER		
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)
occurrences causally related to treatment / all	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
HAEMORRHOIDS		
subjects affected / exposed	4 / 3587 (0.11%)	1 / 3587 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
MELAENA		
subjects affected / exposed	4 / 3587 (0.11%)	1 / 3587 (0.03%)
occurrences causally related to treatment / all	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
RECTAL HAEMORRHAGE		
subjects affected / exposed	4 / 3587 (0.11%)	1 / 3587 (0.03%)
occurrences causally related to treatment / all	1 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
VOMITING		
subjects affected / exposed	0 / 3587 (0.00%)	5 / 3587 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 1
CONSTIPATION		
subjects affected / exposed	1 / 3587 (0.03%)	3 / 3587 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
DIARRHOEA		

subjects affected / exposed	1 / 3587 (0.03%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DIVERTICULUM</b>			
subjects affected / exposed	1 / 3587 (0.03%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DYSPHAGIA</b>			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>NAUSEA</b>			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTRITIS EROSIVE</b>			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HIATUS HERNIA</b>			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>SMALL INTESTINAL OBSTRUCTION</b>			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ABDOMINAL HERNIA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ANAL HAEMORRHAGE</b>			

subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLITIS			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULITIS INTESTINAL HAEMORRHAGIC			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULUM INTESTINAL HAEMORRHAGIC			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTERITIS			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTEROCOLITIS			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL ANGIODYSPLASIA HAEMORRHAGIC			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
IMPAIRED GASTRIC EMPTYING			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
INGUINAL HERNIA, OBSTRUCTIVE			

subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTESTINAL OBSTRUCTION			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTESTINAL PERFORATION			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
PEPTIC ULCER HAEMORRHAGE			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL ADHESIONS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL DISCOMFORT			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL PAIN LOWER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL WALL HAEMATOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHANGE OF BOWEL HABIT			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLITIS ISCHAEMIC			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLITIS ULCERATIVE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULAR PERFORATION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULUM INTESTINAL			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DUODENAL STENOSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DUODENITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
EPIGASTRIC DISCOMFORT			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FOOD POISONING			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRIC ANTRAL VASCULAR ECTASIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRODUODENAL ULCER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRODUODENITIS HAEMORRHAGIC			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL DISORDER			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL NECROSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
GASTROINTESTINAL ULCER HAEMORRHAGE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GINGIVAL BLEEDING			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATEMESIS			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMORRHAGIC EROSIVE GASTRITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ILEUS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INGUINAL HERNIA STRANGULATED			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTESTINAL ISCHAEMIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LARGE INTESTINAL ULCER HAEMORRHAGE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
LARGE INTESTINE PERFORATION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OESOPHAGITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCREATITIS NECROTISING			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PEPTIC ULCER			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERITONEAL HAEMORRHAGE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMOPERITONEUM			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PROCTALGIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RETROPERITONEAL HAEMATOMA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SIGMOIDITIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SMALL INTESTINAL HAEMORRHAGE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SMALL INTESTINAL ULCER HAEMORRHAGE			



subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBILEUS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
UMBILICAL HERNIA, OBSTRUCTIVE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
SKIN ULCER			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETIC FOOT			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
DECUBITUS ULCER			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PSORIASIS			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DERMATITIS ALLERGIC			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ECCHYMOSIS			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PEMPHIGUS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RASH GENERALISED			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SKIN FISSURES			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
RENAL FAILURE ACUTE			
subjects affected / exposed	33 / 3587 (0.92%)	22 / 3587 (0.61%)	
occurrences causally related to treatment / all	12 / 35	4 / 23	
deaths causally related to treatment / all	0 / 0	0 / 3	
RENAL FAILURE			
subjects affected / exposed	14 / 3587 (0.39%)	12 / 3587 (0.33%)	
occurrences causally related to treatment / all	0 / 14	2 / 12	
deaths causally related to treatment / all	0 / 1	0 / 2	
RENAL IMPAIRMENT			
subjects affected / exposed	6 / 3587 (0.17%)	6 / 3587 (0.17%)	
occurrences causally related to treatment / all	3 / 6	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATURIA			
subjects affected / exposed	5 / 3587 (0.14%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	1 / 5	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEPHROLITHIASIS			

subjects affected / exposed	6 / 3587 (0.17%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	1 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL FAILURE CHRONIC			
subjects affected / exposed	5 / 3587 (0.14%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY RETENTION			
subjects affected / exposed	5 / 3587 (0.14%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL COLIC			
subjects affected / exposed	3 / 3587 (0.08%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
CALCULUS URETERIC			
subjects affected / exposed	1 / 3587 (0.03%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
CALCULUS URINARY			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYDRONEPHROSIS			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PRERENAL FAILURE			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL ARTERY STENOSIS			

subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETHRAL STENOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
AZOTAEMIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
BLADDER TAMPONADE			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CYSTITIS HAEMORRHAGIC			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETIC NEPHROPATHY			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NEPHRITIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL CYST			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY TRACT OBSTRUCTION			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINOMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
HYPERTHYROIDISM			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
ADRENOCORTICAL INSUFFICIENCY ACUTE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
No Coding available			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
OSTEOARTHRITIS			
subjects affected / exposed	14 / 3587 (0.39%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 14	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	6 / 3587 (0.17%)	9 / 3587 (0.25%)	
occurrences causally related to treatment / all	0 / 6	2 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
BACK PAIN			
subjects affected / exposed	2 / 3587 (0.06%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	

INTERVERTEBRAL DISC PROTRUSION			
subjects affected / exposed	7 / 3587 (0.20%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULOSKELETAL PAIN			
subjects affected / exposed	2 / 3587 (0.06%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYALGIA			
subjects affected / exposed	2 / 3587 (0.06%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	1 / 2	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHRITIS			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RHEUMATOID ARTHRITIS			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL OSTEOARTHRITIS			
subjects affected / exposed	0 / 3587 (0.00%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHRALGIA			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
RHABDOMYOLYSIS			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUMBAR SPINAL STENOSIS			

subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL COLUMN STENOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULAR WEAKNESS			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TENDONITIS			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHRITIS REACTIVE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
EXOSTOSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTERVERTEBRAL DISC DEGENERATION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTERVERTEBRAL DISC DISORDER			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCLE HAEMORRHAGE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCLE SPASMS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYOPATHY			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEOCHONDROSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PALINDROMIC RHEUMATISM			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ROTATOR CUFF SYNDROME			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SCLERODERMA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL DISORDER			



subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL PAIN			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPONDYLITIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SYSTEMIC LUPUS ERYTHEMATOSUS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
PNEUMONIA			
subjects affected / exposed	43 / 3587 (1.20%)	40 / 3587 (1.12%)	
occurrences causally related to treatment / all	0 / 47	0 / 45	
deaths causally related to treatment / all	0 / 3	0 / 3	
CELLULITIS			
subjects affected / exposed	24 / 3587 (0.67%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 27	1 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY TRACT INFECTION			
subjects affected / exposed	12 / 3587 (0.33%)	20 / 3587 (0.56%)	
occurrences causally related to treatment / all	0 / 14	0 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEPSIS			
subjects affected / exposed	5 / 3587 (0.14%)	10 / 3587 (0.28%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 1	0 / 2	
SEPTIC SHOCK			

subjects affected / exposed	4 / 3587 (0.11%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 3	0 / 5	
<b>BRONCHITIS</b>			
subjects affected / exposed	4 / 3587 (0.11%)	7 / 3587 (0.20%)	
occurrences causally related to treatment / all	0 / 4	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LOCALISED INFECTION</b>			
subjects affected / exposed	4 / 3587 (0.11%)	6 / 3587 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GANGRENE</b>			
subjects affected / exposed	3 / 3587 (0.08%)	6 / 3587 (0.17%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTROENTERITIS</b>			
subjects affected / exposed	7 / 3587 (0.20%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>RESPIRATORY TRACT INFECTION</b>			
subjects affected / exposed	5 / 3587 (0.14%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BRONCHOPNEUMONIA</b>			
subjects affected / exposed	5 / 3587 (0.14%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>LOWER RESPIRATORY TRACT INFECTION</b>			
subjects affected / exposed	5 / 3587 (0.14%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>OSTEOMYELITIS</b>			

subjects affected / exposed	2 / 3587 (0.06%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
APPENDICITIS			
subjects affected / exposed	3 / 3587 (0.08%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
POSTOPERATIVE WOUND INFECTION			
subjects affected / exposed	4 / 3587 (0.11%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
WOUND INFECTION			
subjects affected / exposed	4 / 3587 (0.11%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ERYSIPELAS			
subjects affected / exposed	0 / 3587 (0.00%)	5 / 3587 (0.14%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUNG INFECTION			
subjects affected / exposed	3 / 3587 (0.08%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
DENGUE FEVER			
subjects affected / exposed	4 / 3587 (0.11%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIVERTICULITIS			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYELONEPHRITIS ACUTE			

subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUBCUTANEOUS ABSCESS			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHRITIS BACTERIAL			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROINTESTINAL INFECTION			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
MEDIASTINITIS			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ORCHITIS			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYELONEPHRITIS			
subjects affected / exposed	2 / 3587 (0.06%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STAPHYLOCOCCAL SEPSIS			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
UPPER RESPIRATORY TRACT INFECTION			

subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
UROSEPSIS			
subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABSCESS			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABSCESS LIMB			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABSCESS NECK			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ACUTE TONSILLITIS			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ANAL ABSCESS			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
BACTERAEEMIA			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENDOCARDITIS			

subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
IMPLANT SITE INFECTION			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTED SKIN ULCER			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE			
subjects affected / exposed	0 / 3587 (0.00%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFLUENZA			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIRECTAL ABSCESS			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERITONITIS			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
PHARYNGITIS			
subjects affected / exposed	1 / 3587 (0.03%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRACHEOBRONCHITIS			

subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ABDOMINAL WALL INFECTION</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ACQUIRED IMMUNODEFICIENCY SYNDROME</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ACTINOMYCOSIS</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>ATYPICAL PNEUMONIA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BACTERIAL SEPSIS</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>BONE TUBERCULOSIS</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BREAST ABSCESS</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BRONCHITIS BACTERIAL</b>			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BURSITIS INFECTIVE</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CANDIDA PNEUMONIA</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CANDIDA SEPSIS</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CELLULITIS OF MALE EXTERNAL GENITAL ORGAN</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CELLULITIS STREPTOCOCCAL</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CHEST WALL ABSCESS</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CYSTITIS</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CHOLECYSTITIS INFECTIVE</b>			



subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE RELATED INFECTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETIC FOOT INFECTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
EAR TUBERCULOSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENDOMETRITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENDOCARDITIS BACTERIAL			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENDOPHTHALMITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ESCHERICHIA BACTERAEMIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ESCHERICHIA URINARY TRACT INFECTION			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTROENTERITIS ROTAVIRUS</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTROENTERITIS VIRAL</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GENITOURINARY TRACT INFECTION</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GRAFT INFECTION</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HAEMATOMA INFECTION</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HERPES ZOSTER</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>INCISION SITE CELLULITIS</b>			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HISTOPLASMOSIS</b>			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTESTINAL GANGRENE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
KLEBSIELLA SEPSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LIVER ABSCESS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOWER RESPIRATORY TRACT INFECTION VIRAL			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
LUDWIG ANGINA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MASTOIDITIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NASAL ABSCESS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NECROTISING FASCIITIS			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
NEUROCYSTICERCOSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
OTITIS MEDIA CHRONIC			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PARONYCHIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIODONTITIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERITONITIS BACTERIAL			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
PERITONSILLAR ABSCESS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PILONIDAL CYST			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONIA KLEBSIELLA			

subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL CELLULITIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL INFECTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
POST PROCEDURAL PNEUMONIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PSEUDOMEMBRANOUS COLITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY SEPSIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
PULMONARY TUBERCULOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYONEPHROSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SALPINGITIS			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SCROTAL ABSCESS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SKIN INFECTION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SOFT TISSUE INFECTION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STAPHYLOCOCCAL BACTERAEMIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STAPHYLOCOCCAL INFECTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STERNITIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STREPTOCOCCAL ABSCESS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
TYPHOID FEVER			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETERITIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY TRACT INFECTION PSEUDOMONAL			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VARICELLA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIRAL INFECTION			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIRAL SINUSITIS			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
WOUND INFECTION STAPHYLOCOCCAL			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
HYPOGLYCAEMIA			
subjects affected / exposed	39 / 3587 (1.09%)	17 / 3587 (0.47%)	
occurrences causally related to treatment / all	20 / 42	6 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERGLYCAEMIA			

subjects affected / exposed	8 / 3587 (0.22%)	10 / 3587 (0.28%)	
occurrences causally related to treatment / all	0 / 8	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEHYDRATION			
subjects affected / exposed	7 / 3587 (0.20%)	8 / 3587 (0.22%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETES MELLITUS INADEQUATE CONTROL			
subjects affected / exposed	3 / 3587 (0.08%)	9 / 3587 (0.25%)	
occurrences causally related to treatment / all	0 / 4	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOKALAEMIA			
subjects affected / exposed	2 / 3587 (0.06%)	4 / 3587 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETES MELLITUS			
subjects affected / exposed	1 / 3587 (0.03%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERKALAEMIA			
subjects affected / exposed	3 / 3587 (0.08%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOMAGNESAEMIA			
subjects affected / exposed	2 / 3587 (0.06%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIABETIC KETOACIDOSIS			
subjects affected / exposed	0 / 3587 (0.00%)	3 / 3587 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPONATRAEMIA			



subjects affected / exposed	1 / 3587 (0.03%)	2 / 3587 (0.06%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
FLUID OVERLOAD			
subjects affected / exposed	2 / 3587 (0.06%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DECREASED APPETITE			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FLUID RETENTION			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERPHOSPHATAEMIA			
subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOCALCAEMIA			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
KETOACIDOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
METABOLIC ACIDOSIS			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TYPE 2 DIABETES MELLITUS			

subjects affected / exposed	0 / 3587 (0.00%)	1 / 3587 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>OBESITY</b>			
subjects affected / exposed	1 / 3587 (0.03%)	0 / 3587 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Aleglitazar	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1514 / 3587 (42.21%)	1119 / 3587 (31.20%)	
Investigations			
WEIGHT INCREASED			
subjects affected / exposed	395 / 3587 (11.01%)	171 / 3587 (4.77%)	
occurrences (all)	417	180	
BLOOD CREATININE INCREASED			
subjects affected / exposed	231 / 3587 (6.44%)	93 / 3587 (2.59%)	
occurrences (all)	279	105	
Vascular disorders			
HYPERTENSION			
subjects affected / exposed	165 / 3587 (4.60%)	183 / 3587 (5.10%)	
occurrences (all)	182	197	
Cardiac disorders			
ANGINA PECTORIS			
subjects affected / exposed	220 / 3587 (6.13%)	223 / 3587 (6.22%)	
occurrences (all)	253	258	
General disorders and administration site conditions			
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	198 / 3587 (5.52%)	224 / 3587 (6.24%)	
occurrences (all)	248	265	
OEDEMA PERIPHERAL			
subjects affected / exposed	470 / 3587 (13.10%)	225 / 3587 (6.27%)	
occurrences (all)	544	266	

Metabolism and nutrition disorders			
HYPOGLYCAEMIA			
subjects affected / exposed	579 / 3587 (16.14%)	389 / 3587 (10.84%)	
occurrences (all)	1555	1004	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 February 2013	Added a study drug discontinuation criterion for patients who experienced a serious GI hemorrhage. This was done to address advice received from the Data Safety Monitoring Board. 25-Feb-2013

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported